Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1977)	10/16/2007 9:27:00 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ANSV Is also acting well on pre-market. (up 9%) After some news. bigcharts.marketwatch.com AP Anesiva Says Zingo Effective in Study Tuesday October 16, 8:54 am ET Anesiva Says Data Show Zingo Eased Venous Access Pain in Adults in Late-Stage Study SOUTH SAN FRANCISCO, Calif. (AP) -- Drug developer Anesiva Inc. said Tuesday its pain treatment Zingo showed positive results in a late-stage study on patients receiving intravenous service or drawing blood through a needle. The PIII involved 699 adult patients. The drug is already approved for children ages 3 to 18 years and is expected to be commercially available in the second quarter of 2008. Anesiva plans to file a supplemental new drug application to use the product in adults with the Food and Drug Administration in the first quarter 2008. Snip It seems the stock may get back to the $15 level.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (1977)	1/15/2008 1:33:12 PM
From: Jibacoa	Read Replies (3) \| Respond to of 3722

ASTM was up 15.09% at its intraday H, but is up only 13% at present.<g> Volume is still < half its ADV. bigcharts.marketwatch.com It announced that the first patient has been treated with its autologous stem cell therapy for dilated cardiomyopathy. That is the first human application of Aastrom's CRC. CRCs are derived from a sample of patient's bone marrow that is processed using its Tissue Repair Cell technology to generate large numbers of stem and early progenitor cells. In February 2007, CRCs received an Orphan Drug Designation from the FDA for use in the treatment of DCM. ASTM also has development programs using TRC-based products for vascular, bone and neural tissue regeneration applications. The stock is trying to get off from the DT coming from its Oct4 H at $1.43 If it can get back above $1 it would be a good % gain.<g> bigcharts.marketwatch.com Bernard